How has been the historical performance of Trident Texofab?

Nov 12 2025 11:32 PM IST
share
Share Via
Trident Texofab has shown consistent growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with total assets rising to 100.58 Cr and earnings per share improving to 1.85. The company also reduced its total debt, indicating enhanced financial health and profitability.
Answer:
The historical performance of Trident Texofab shows a steady increase in net sales and total operating income over the years, with net sales rising from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. The total operating income followed a similar trend, reaching 122.06 Cr in Mar'25 from 49.93 Cr in Mar'21. Operating profit (PBDIT) also saw fluctuations, peaking at 8.78 Cr in Mar'25, although it was lower than the previous year's 8.21 Cr. Profit before tax increased to 2.58 Cr in Mar'25, up from 1.17 Cr in Mar'24, while profit after tax rose to 2.51 Cr from 1.08 Cr in the same period. The company's total assets grew significantly from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, reflecting a robust expansion strategy. However, total debt decreased from 36.96 Cr in Mar'24 to 26.50 Cr in Mar'25, indicating improved financial health. The earnings per share (EPS) increased to 1.85 in Mar'25 from 1.07 in Mar'24, showcasing enhanced profitability per share.

Breakdown:
Trident Texofab's financial performance demonstrates a consistent upward trajectory in net sales, which increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 122.06 Cr in Mar'25. Operating profit (PBDIT) fluctuated, peaking at 8.78 Cr in Mar'25, while profit before tax rose to 2.58 Cr, reflecting improved operational efficiency. The company's total assets expanded significantly to 100.58 Cr in Mar'25, up from 55.68 Cr in Mar'20, while total debt decreased, suggesting a strengthening balance sheet. Earnings per share also improved, reaching 1.85 in Mar'25, highlighting the company's ability to generate profit for its shareholders. Overall, Trident Texofab's financial metrics indicate a positive growth trend and enhanced profitability over the years.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is Trident Texofab technically bullish or bearish?
Dec 04 2025 08:47 AM IST
share
Share Via
How has been the historical performance of Trident Texofab?
Dec 03 2025 10:55 PM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Nov 19 2025 08:10 AM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Nov 18 2025 08:26 AM IST
share
Share Via
Why is Trident Texofab falling/rising?
Nov 17 2025 11:34 PM IST
share
Share Via